19th European AIDS Conference (EACS 2023)

18 October 2023 - 21 November 2023

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial

05 Dec 2023 bởi

Four-day-a-week dosing of dual therapy for HIV performs similarly to daily doses in terms of sustaining viral suppression in the DUETTO trial. However, virological failure (VF) and drug resistance rates were higher with the 4-day/week dosing regimen.

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial

05 Dec 2023

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023 bởi

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023 bởi

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023